FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3124395146> ?p ?o ?g. }

• W3124395146 abstract "Objective: The study aimed to explore the bioequivalence of a proposed biosimilar BAT1806 to its reference products marketed in the EU and US (RoActemra-EU and Actemra-US) among healthy Chinese men. The tolerance, immunogenicity, and pharmacokinetics (PK) of the three drugs were also investigated. Methods: In this randomized, double-blind, single-dose, three-arm, parallel study, a single-dose of 4 mg/kg of the reference products, or the biosimilar was administered to the participants. The participants were followed up for 57 days, and PK, immunogenicity, and tolerance evaluations were completed during this period. Results: The PK parameters were similar in all three groups: BAT1806 ( n = 45), RoActemra-EU ( n = 42), and Actemra-US ( n = 42). The 90% confidence intervals (CIs) for the ratios of C max , AUC 0– t and AUC 0–∞ were 86.90–104.41% for BAT1806 vs. RoActemra-EU, 91.70–106.15% for BAT1806 vs Actemra-US, and 90.04–105.53% for Actemra-US vs RoActemra-EU. For all comparisons, the 90% CIs for the C max , AUC 0– t , and AUC 0–∞ were within the predefined bioequivalence limit of 80.00–125.00%. The intersubject variability ranged from 14.5% to 21.5%, which was considerably low. Among the participants, 19 (42.2%), 10 (23.8%), and 12 (28.6%) from the BAT1806, RoActemra-EU, and Actemra-US groups were, respectively, found to be positive for anti-drug antibodies, while 14 (31.1%), nine (21.4%), and 12 (28.6%) were positive for neutralizing antibodies. Nevertheless, these antibodies did not affect the drug concentrations, and the outcomes in the bioequivalence tests were similar after sensitivity analysis. Treatment-related and treatment-emergent adverse events (TEAEs) were recorded in 27, 34, and 32 participants in the BAT1806, RoActemra-EU, and Actemra-US groups, respectively. The most common treatment-related adverse events observed were a decrease in neutrophil, and white blood cell counts. Conclusion: The PK characteristics of BAT1806 were similar to those of the reference products, RoActemra-EU and Actemra-US. Both BAT1806 and the reference products exhibited low intersubject variability and similar safety profiles. Clinical trial registration number: http://www.chinadrugtrials.org.cn/index.html , CTR20180039; https://clinicaltrials.gov/NCT03606876" @default.
• W3124395146 created "2021-02-01" @default.
• W3124395146 creator A5003123045 @default.
• W3124395146 creator A5019034073 @default.
• W3124395146 creator A5024542160 @default.
• W3124395146 creator A5031085527 @default.
• W3124395146 creator A5033020983 @default.
• W3124395146 creator A5057603213 @default.
• W3124395146 creator A5061463319 @default.
• W3124395146 creator A5063918608 @default.
• W3124395146 creator A5064530138 @default.
• W3124395146 creator A5064681608 @default.
• W3124395146 creator A5076636013 @default.
• W3124395146 creator A5078861675 @default.
• W3124395146 creator A5080144369 @default.
• W3124395146 creator A5086032916 @default.
• W3124395146 date "2021-01-25" @default.
• W3124395146 modified "2023-10-16" @default.
• W3124395146 title "A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men" @default.
• W3124395146 cites W1566149917 @default.
• W3124395146 cites W1579629528 @default.
• W3124395146 cites W2010090350 @default.
• W3124395146 cites W2011709831 @default.
• W3124395146 cites W2023761225 @default.
• W3124395146 cites W2065441164 @default.
• W3124395146 cites W2510563610 @default.
• W3124395146 cites W2606204120 @default.
• W3124395146 cites W2765166506 @default.
• W3124395146 cites W2791224008 @default.
• W3124395146 cites W2791731545 @default.
• W3124395146 cites W2794173683 @default.
• W3124395146 cites W2902934983 @default.
• W3124395146 cites W2905076420 @default.
• W3124395146 cites W2942854317 @default.
• W3124395146 cites W3033780627 @default.
• W3124395146 cites W3040851638 @default.
• W3124395146 doi "https://doi.org/10.3389/fphar.2020.609522" @default.
• W3124395146 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7868548" @default.
• W3124395146 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33569002" @default.
• W3124395146 hasPublicationYear "2021" @default.
• W3124395146 type Work @default.
• W3124395146 sameAs 3124395146 @default.
• W3124395146 citedByCount "6" @default.
• W3124395146 countsByYear W31243951462022 @default.
• W3124395146 countsByYear W31243951462023 @default.
• W3124395146 crossrefType "journal-article" @default.
• W3124395146 hasAuthorship W3124395146A5003123045 @default.
• W3124395146 hasAuthorship W3124395146A5019034073 @default.
• W3124395146 hasAuthorship W3124395146A5024542160 @default.
• W3124395146 hasAuthorship W3124395146A5031085527 @default.
• W3124395146 hasAuthorship W3124395146A5033020983 @default.
• W3124395146 hasAuthorship W3124395146A5057603213 @default.
• W3124395146 hasAuthorship W3124395146A5061463319 @default.
• W3124395146 hasAuthorship W3124395146A5063918608 @default.
• W3124395146 hasAuthorship W3124395146A5064530138 @default.
• W3124395146 hasAuthorship W3124395146A5064681608 @default.
• W3124395146 hasAuthorship W3124395146A5076636013 @default.
• W3124395146 hasAuthorship W3124395146A5078861675 @default.
• W3124395146 hasAuthorship W3124395146A5080144369 @default.
• W3124395146 hasAuthorship W3124395146A5086032916 @default.
• W3124395146 hasBestOaLocation W31243951461 @default.
• W3124395146 hasConcept C105639569 @default.
• W3124395146 hasConcept C111113717 @default.
• W3124395146 hasConcept C112705442 @default.
• W3124395146 hasConcept C126322002 @default.
• W3124395146 hasConcept C144133560 @default.
• W3124395146 hasConcept C159654299 @default.
• W3124395146 hasConcept C203014093 @default.
• W3124395146 hasConcept C22979827 @default.
• W3124395146 hasConcept C2780868878 @default.
• W3124395146 hasConcept C2910001868 @default.
• W3124395146 hasConcept C42404028 @default.
• W3124395146 hasConcept C44249647 @default.
• W3124395146 hasConcept C59491497 @default.
• W3124395146 hasConcept C71924100 @default.
• W3124395146 hasConcept C90924648 @default.
• W3124395146 hasConcept C98274493 @default.
• W3124395146 hasConceptScore W3124395146C105639569 @default.
• W3124395146 hasConceptScore W3124395146C111113717 @default.
• W3124395146 hasConceptScore W3124395146C112705442 @default.
• W3124395146 hasConceptScore W3124395146C126322002 @default.
• W3124395146 hasConceptScore W3124395146C144133560 @default.
• W3124395146 hasConceptScore W3124395146C159654299 @default.
• W3124395146 hasConceptScore W3124395146C203014093 @default.
• W3124395146 hasConceptScore W3124395146C22979827 @default.
• W3124395146 hasConceptScore W3124395146C2780868878 @default.
• W3124395146 hasConceptScore W3124395146C2910001868 @default.
• W3124395146 hasConceptScore W3124395146C42404028 @default.
• W3124395146 hasConceptScore W3124395146C44249647 @default.
• W3124395146 hasConceptScore W3124395146C59491497 @default.
• W3124395146 hasConceptScore W3124395146C71924100 @default.
• W3124395146 hasConceptScore W3124395146C90924648 @default.
• W3124395146 hasConceptScore W3124395146C98274493 @default.
• W3124395146 hasFunder F4320335960 @default.
• W3124395146 hasLocation W31243951461 @default.
• W3124395146 hasLocation W31243951462 @default.
• W3124395146 hasLocation W31243951463 @default.
• W3124395146 hasOpenAccess W3124395146 @default.
• W3124395146 hasPrimaryLocation W31243951461 @default.
• W3124395146 hasRelatedWork W124377181 @default.

• next